ArticleOncoimmunology2016
Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.
Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Soluble NKG2DLs Are Elevated in Breast Cancer Patients and Associate with Disease Outcome.International journal of molecular sciences · 2024Article
- Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance.Frontiers in oncology · 2022Review
- Review
- Leveraging NKG2D Ligands in Immuno-Oncology.Frontiers in immunology · 2021Review
- Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMICJournal for immunotherapy of cancer · 2019Article
- Past, Current, and Future of Immunotherapies for Prostate Cancer.Frontiers in oncology · 2019Review
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.Seminars in cancer biology · 2018Review
- NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.Frontiers in immunology · 2018Review
- Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.Neoplasia (New York, N.Y.) · 2017Article
- Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Science advances · 2017Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human tumor-derived soluble NKG2D sMIC paralyzes the immune system through multiple pathways. Targeting soluble MIC with a nonblocking sMIC-neutralizing anti-MIC antibody effectuated and revamped endogenous innate and adoptive antitumor responses. Therapy induced regression of primary tumors and eliminated metastasis in preclinical models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.